Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma of Lung 1

Interventions

Bevacizumab 77Fluorouracil 55Cetuximab 48Oxaliplatin 43Leucovorin 42pembrolizumab 37Irinotecan 33Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 19trifluridine tipiracil drug combination 17Panitumumab 15Blood Specimen Collection 15Nivolumab 14Magnetic Resonance Spectroscopy 14regorafenib 13Biopsy 13Trifluridine 12Gemcitabine 12Cisplatin 12Standard of Care 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 10Cyclophosphamide 9tislelizumab 8Trastuzumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × devimistat × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡